MoonLake Immunotherapeutics (MLTX) Change in Account Payables (2021 - 2026)

MoonLake Immunotherapeutics' Change in Account Payables history runs 6 years deep, the most recent figure standing at -$6.2 million for Q1 2026.

• In Q1 2026, Change in Account Payables fell 304.88% year-over-year to -$6.2 million; the TTM figure through Mar 2026 stood at $11.4 million (up 33.45% YoY), while the FY2025 annual figure was $20.6 million, up 187.35% from the prior year.
• Change in Account Payables for Q1 2026 stood at -$6.2 million, down from $4.3 million in the prior quarter.
• The five-year high for Change in Account Payables was $8.2 million in Q3 2025, with the low at -$6.2 million in Q1 2026.
• The 5-year median for Change in Account Payables is $1.6 million (2024), against an average of $1.3 million.
• The sharpest annual moves came in 2023 and 2024: Change in Account Payables tumbled 460.19% in 2023, then jumped 682.92% in 2024.
• MoonLake Immunotherapeutics' Change in Account Payables stood at -$801281.0 in 2022, then plunged by 95.53% to -$1.6 million in 2023, then decreased by 9.65% to -$1.7 million in 2024, then soared by 348.54% to $4.3 million in 2025, then slumped by 244.57% to -$6.2 million in 2026.
• Business Quant data shows MLTX's Change in Account Payables at -$6.2 million in Q1 2026, $4.3 million in Q4 2025, and $8.2 million in Q3 2025.